Ignite Creation Date:
2025-12-24 @ 5:28 PM
Ignite Modification Date:
2026-01-02 @ 11:43 AM
Study NCT ID:
NCT04118868
Status:
UNKNOWN
Last Update Posted:
2022-10-12
First Post:
2019-10-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Sponsor:
Sorrento Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-31
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-03-27
Completion Date Type:
ESTIMATED
First Submit Date:
2019-10-04
First Submit QC Date:
None
Study First Post Date:
2019-10-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-07
Last Update Post Date:
2022-10-12
Last Update Post Date Type:
ACTUAL